Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related adverse reactions in the nervous system
Open Access
- 10 December 2019
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 11 (2) , 481-487
Abstract
Immune checkpoint inhibitors (ICIs) can cause adverse reactions in the nervous system. The incidence rate is 0.1%–12% and 80% of nervous system adverse reactions occur within the first four months of application. ICIs can cause diseases of various parts of the nervous system including central nervous system diseases such as aseptic meningitis, meningeal encephalitis, necrotizing encephalitis, brainstem encephalitis, transverse myelitis, etc., and peripheral neuropathy such as cranial nerve peripheral neuropathy, multifocal nerve root neuropathy, Guillain‐Barré syndrome, spinal nerve root neuropathy, myasthenia gravis, myopathy, etc. For these complications of the nervous system, diagnosis could be difficult. Physicians require a specific collection of nervous system symptoms and signs, combined with supplementary examinations including imaging, cerebrospinal fluid cytology, EEG or electromyography in order to exclude infection or malignant tumor before reaching a final diagnosis. With regard to treatment, ICIs should be discontinued in severe cases, and large doses of glucocorticoid or gamma globulin administered, and supportive treatment may be necessary. If severe adverse reactions of the nervous system occur, the prognosis could be poor.Keywords
This publication has 24 references indexed in Scilit:
- Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapyCurrent Opinion in Neurology, 2019
- Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the LiteratureFrontiers in Immunology, 2018
- Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic MelanomaThe Oncologist, 2017
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literatureEuropean Journal of Cancer, 2017
- Neurologic complications of immune checkpoint inhibitorsCurrent Opinion in Neurology, 2016
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic CancerJAMA Neurology, 2016
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyEuropean Journal of Cancer, 2016
- Limbic encephalitis following immunotherapy against metastatic malignant melanomaBMJ Case Reports, 2016
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insightsPituitary, 2015
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2015